Skip to search formSkip to main contentSkip to account menu

ganitumab

A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

AMG 479
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract GS3-08: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL
Background: Pathological complete response (pCR) is accepted by FDA as a surrogate endpoint for accelerated approval of targeted… 
Review
2017
Review
2017
Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials
Abstract Background: Prognosis of advanced pancreatic cancer is dismal and the novel targeted therapies, albeit successfully used… 
2014
2014
IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.
Ganitumab is a fully human MAB to the human type 1 IGF receptor (IGF1R). Binding assays showed that ganitumab recognized murine… 
Review
2014
Review
2014
Ganitumab for the treatment of small-cell lung cancer
Introduction: Small-cell lung cancer (SCLC) accounts for 15 – 20% of all lung cancer cases with few advances made in the systemic… 
2013
2013
A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line…
5515 Background: IGF signaling has been implicated in the pathogenesis and progression of ovarian cancer (OC). Single agent… 
2013
2013
Therapy: Blockade of IGF-1R—not effective in neuroendocrine tumours
A phase II trial has demonstrated that insulin-like growth factor 1 receptor (IGF-1R) blockade in advanced neuroendocrine tumours… 
2013
2013
Differential Pharmacokinetics of Ganitumab in Patients With Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers
Ganitumab is an investigational, fully human monoclonal antibody antagonist of the insulin‐like growth factor‐1 receptor (IGF1R… 
2012
2012
Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers
2012
2012
The impact of timing of EGFR and IGF-1R inhibition for sensitizing head and neck cancer to radiation.
BACKGROUND Targeting the epidermal growth factor receptor (EGFR) improved radiotherapy outcome by 10-15% in head and neck tumors… 
2012
2012
FDA prevails in stem cell trial
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)